Year: 2024
Type: article
Study design: Observational Study
Source: Annals of Oncology
Institutions: Froedtert Hospital, Medical College of Wisconsin, Caris Life Sciences (United States), University Hospitals of Cleveland, University Hospitals Seidman Cancer Center, University of Alabama at Birmingham, UAB Medicine, National Cancer Institute, Center for Cancer Research, University of Southern California, USC Norris Comprehensive Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, European Association for Cancer Research, Gilead Sciences, American Society of Clinical Oncology, Celgene, FibroGen, F. Hoffmann-La Roche, OncoMed Pharmaceutical, Array BioPharma, Regeneron Pharmaceuticals, Merck KGaA, Taiho Pharmaceutical, Exelixis, European SocieTy for Radiotherapy and Oncology, Novocure, Les Laboratories Pierre Fabre, Agios Pharmaceuticals, Mirati Therapeutics, BeiGene, Incyte, F-star Therapeutics, MacroGenics, Seagen, Eisai, European Society for Medical Oncology, Sociedad Española de Oncología Médica, Servier, Novartis Farmacéutica, PharmaMar, Menarini Group, Ipsen, Grifols, LEO Pharma, Genentech, Pharmacyclics, Takeda Pharmaceuticals International, Loxo Oncology, Foundation Medicine, Daiichi Sankyo Europe, Cilag
OpenAlex ID: W4402561619